Augmentation in Tx-resistant OCD: an Open Label Trial
This study examines the use of Acamprosate (Campral(R)) in the treatment of Obsessive Compulsive Disorder (OCD). The treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. Such patients are referred to as having treatment resistant OCD.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial|
- Acamprosate would be efficacious for SSRI resistant OCD symptoms [ Time Frame: Patients will be administered 12 weeks of Acamprosate. ] [ Designated as safety issue: Yes ]
- Acamprosate would improve anxiety, depressive symptoms and quality of life in OCD. [ Time Frame: Patients will be administered 12 weeks of Acamprosate ] [ Designated as safety issue: No ]
|Study Start Date:||April 2006|
|Study Completion Date:||October 2009|
|Primary Completion Date:||October 2009 (Final data collection date for primary outcome measure)|
A patient will receive study drug for about 12 weeks. Throughout the study, the study doctor, on best medical judgment, may gradually increase or decrease the dose of the study medication. The adjustments will dependent on the subject's response and whether the subject has side effects. Once the subject has completed treatment under this study, the subject may resume standard treatment for his/her obsessive compulsive disorder by their regular doctor.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00590642
|United States, Nebraska|
|Creighton University Department of Psychiatry|
|Omaha, Nebraska, United States, 68131|
|Principal Investigator:||Sriram Ramaswamy, MD||Creighton University|